Types of surveillance by cancer type:
Colorectal cancer:
history & physical exam, CEA, and CT scan⁴
Breast cancer:
history & physical exam
and mammography²
Lung cancer:
history & physical exam and chest CT scan³
Integrate MRD testing into existing guideline-recommended surveillance for colorectal, breast, and lung
cancers.1-3*
Supplement current standard-of-care surveillance practices over the first 5 years.2-4*
Talk with a booth representative to discover more about MRD detection and ctDNA monitoring with Guardant Reveal.
CEA, carcinoembryonic antigen; CT, computerized tomography;
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Product availability may vary depending on region.
*For invasive carcinomas and inflammatory breast cancers and non-small cell lung cancer (adenocarcinoma, large cell, and squamous).5,6